Nonimmune Fetal Hydrops
- Presence of excess extracellular fluid in at least two fetal compartments (ascites, pleural effusion, pericardial effusion, skin edema, polyhydramnios) without any identifiable circulating antibody to red-cell antigens.
- For a discussion on immune-mediated disease, see Chapter 37.
- Prevalence is estimated at 1:1500-4000.
- Highest prevalence in Southeast Asian population.
Conditions Associated with Nonimmune Fetal Hydrops
Affected System |
Approx. % of Cases (in third trimester) |
Examples | |
---|---|---|---|
Cardiac |
20% |
Fetal arrhythmias (bradyarrhythmias and tachyarrhythmias) Structural cardiac defects causing congestive failure Extrinsic compression of heart causing low output states → leads to fetal tachyarrhythmia → high-output failure → hydrops Myocarditis | |
Renal |
5% |
Nephrosis Renal hypoplasia/aplasia |
Renal vein thrombosis Obstructive uropathies |
Infection |
8% |
Toxoplasmosis Herpes simplex virus Syphilis Adenovirus |
Rubella CMV Hepatitis Parvovirus |
Pulmonary |
5% |
Congenital chylothorax Pulmonary lymphangiectasia |
Congenital diaphragmatic hernia Cystic adenomatoid malformations |
Other intrathoracic masses (eg, pulmonary sequestration) that cause compression of thoracic blood vessels → obstructive venous flow → hydrops | |||
Placenta/cord |
Rare |
Chorangioma Arteriovenous malformation Significant cord compression |
Umbilical vein thrombosis True umbilical cord knot |
Maternal conditions |
5% |
Diabetes mellitus Severe preeclampsia/ eclampsia |
Hyperthyroidism |
Gastrointestinal |
5% |
In utero midgut volvulus |
Bowel atresias |
Chromosomal |
10% |
Turner syndrome Aneuploidy |
Trisomies 13, 18, 21 Noonan Syndrome |
Miscellaneous |
10% |
Congenital myopathies Inborn errors of metabolism CNS malformations |
Skeletal dysplasias Abdominal neoplasms |
Unknown |
20% |
- Increased uterine size for dates
- Decreased fetal movements
- Generalized maternal edema (mirror syndrome)
- Polyhydramnios (AFI >24)
- Placentomegaly
- Infants with nonimmune hydrops are at very high risk for fetal demise.
- Intrauterine therapy is aimed at treating underlying causes (maternal digitalis therapy for fetal tachyarrhythmias); if this is not possible, the risks of intrauterine death versus premature delivery have to be weighed.
- By organ system (see table below).
Management of Nonimmune Fetal Hydrops by Organ System
System |
Potential Difficulties/Management |
---|---|
Pulmonary |
|
Cardiovascular |
|
Fluids and electrolytes |
|
| |
Hematology |
|
Infectious disease |
|
Renal |
|

Stay updated, free articles. Join our Telegram channel

Full access? Get Clinical Tree

